Novo Nordisk hasn't yet released the full trial results, but the study may be compelling enough to get insurance companies to provide coverage for the expensive medication, said Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Bariatric Center in New Orleans.
in the U.S. The evidence that Wegovy can reduce heart risks along with weight loss may change some views that it's a vanity drug, said Dr. Holly Lofton, the director of the weight management program at NYU Langone Health and an investigator in the Novo Nordisk trial.The findings were based on a late-stage clinical trial of more than 17,000 adults ages 45 and up who got a 2.4-milligram dose of Wegovy or a placebo in addition to standard care.
हमने इस समाचार को संक्षेप में प्रस्तुत किया है ताकि आप इसे तुरंत पढ़ सकें। यदि आप समाचार में रुचि रखते हैं, तो आप पूरा पाठ यहां पढ़ सकते हैं। और पढो: